Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

8.265 -0.215 (-2.53%)

Streaming Delayed Price Updated: 11:09 AM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022 ↗

February 18, 2022

Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago...

Via Benzinga

How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months? ↗

February 17, 2022

Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020,...

Via Benzinga

Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗

February 17, 2022

Can the formerly red-hot biotech segment return to its previous glory?

Via Investor's Business Daily

Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion ↗

February 15, 2022

Intellia will receive up to $920 million in payments for five potential treatments.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2022 ↗

February 07, 2022

Upgrades For Enova International Inc (NYSE:ENVA), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61,...

Via Benzinga

Analyst Ratings For Intellia Therapeutics ↗

January 31, 2022

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗

February 14, 2022

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 01, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today ↗

January 13, 2022

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 32.37% on an annualized basis. Buying $1,000 In NTLA: 5 years ago, an investor could have...

Via Benzinga

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

What 4 Analyst Ratings Have To Say About Intellia Therapeutics ↗

January 07, 2022

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 05, 2022

Gainers SomaLogic (NASDAQ:SLGC) shares mo...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗

January 07, 2022

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:

Via Benzinga

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

54 Biggest Movers From Yesterday ↗

December 08, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...

Via Benzinga

36 Stocks Moving In Tuesday's Mid-Day Session ↗

December 07, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories....

Via Benzinga

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗

November 21, 2021

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Via The Motley Fool

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript ↗

November 06, 2021

NTLA earnings call for the period ending October 3, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock ↗

October 18, 2021

David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What...

Via Benzinga

Topics Regulatory Compliance

2 Gene-Editing Stocks to Have on Your Radar Right Now ↗

October 17, 2021

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Via The Motley Fool

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗

October 15, 2021

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Via The Motley Fool

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today